STOK
NASDAQStoke Therapeutics Inc.
Price$32.70+0.07 (+0.21%)
01:30 PM07:45 PM
News · 26 weeks84-55%
2025-11-022026-04-26
Mix4990d
- Insider22(45%)
- Other13(27%)
- SEC Filings10(20%)
- Analyst2(4%)
- Leadership1(2%)
- Earnings1(2%)
Latest news
25 items- PRStoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial UpdatesStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that management will host a webcast and conference call for analysts and investors on Thursday, May 7, 2026, at 4:30 p.m. ET, to discuss first quarter 2026 business and financial updates. The webcast will be available on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Research analysts who plan to join the call a
- SECSEC Form DEFA14A filed by Stoke Therapeutics Inc.DEFA14A - Stoke Therapeutics, Inc. (0001623526) (Filer)
- SECSEC Form DEF 14A filed by Stoke Therapeutics Inc.DEF 14A - Stoke Therapeutics, Inc. (0001623526) (Filer)
- PRStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on April 15, 2026, it granted stock options to purchase an aggregate of 129,565 shares of common stock to fourteen new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $35.54 per share, which is equal to the closing price o
- PRStoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare ConferenceStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 3:00 p.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke Therape
- PRThe Credibility Filter Wall Street Uses to Sort Biotech WinnersVANCOUVER, British Columbia, April 08, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary — Biotechs that went public in Q1 2026 raised a median of $287.5 million each; and nearly every one of them carried mid or late stage clinical data[1]. That is not a coincidence. The IQVIA Institute's latest annual report found that biopharma dealmaking is now clustering around high value science and companies with credentialed pipelines[2]. It's becoming apparent that smart money is no longer chasing press releases, it's chasing invitations. Conference stage presentations from field defining researchers, peer reviewed journal publications, and stacked regulatory designations have become the fi
- INSIDERSEC Form 4 filed by Kahn Clare4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kahn Clare3 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SECSEC Form 8-K filed by Stoke Therapeutics Inc.8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
- PRStoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of DirectorsStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. "Clare brings more than three decades of industry experience, and we are very pleased to welcome her to the Board at this pivotal time for Stoke," said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. "Clare's deep regulatory strategy and drug development expertise, p
- INSIDERSEC Form 4 filed by Ticho Barry4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SECSEC Form 8-K filed by Stoke Therapeutics Inc.8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
- INSIDERSEC Form 4 filed by Allan Jonathan4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Ticho Barry4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Leggett Thomas4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Hoitt Jason4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 4 filed by Allan Jonathan4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SECSEC Form S-3ASR filed by Stoke Therapeutics Inc.S-3ASR - Stoke Therapeutics, Inc. (0001623526) (Filer)
- INSIDERChief Patient Officer Hoitt Jason converted options into 10,000 shares, increasing direct ownership by 251% to 13,988 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERChief Financial Officer Leggett Thomas converted options into 14,750 shares (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Ticho Barry converted options into 33,850 shares, increasing direct ownership by 171% to 53,648 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERDirector Kaye Edward M. Md converted options into 61,750 shares, increasing direct ownership by 126% to 110,874 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERGENERAL COUNSEL & CORP SEC Allan Jonathan converted options into 25,475 shares, increasing direct ownership by 208% to 37,731 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERDirector Levin Arthur A sold $22,264 worth of shares (605 units at $36.80), decreasing direct ownership by 12% to 4,237 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
STOK FAQ
7 questionsWhat does Stoke Therapeutics Inc. do?
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera...Where does STOK stock trade?
Stoke Therapeutics Inc. (STOK) is listed on NASDAQ.What sector and industry is STOK in?
Stoke Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Stoke Therapeutics Inc. go public?
Stoke Therapeutics Inc. (STOK) completed its IPO in 2019.What are analysts saying about STOK?
Stoke Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Outperform with a $4000.00 price target on 2026-02-24. Recent price targets range from $1800.00 to $4000.00.What companies are similar to STOK?
Notable peers in the same industry include GTHX (G1 Therapeutics Inc.), MCRB (Seres Therapeutics Inc.), GRTX (Galera Therapeutics Inc.). Compare STOK side-by-side with any of them on Quantisnow.How can I track STOK on Quantisnow?
Quantisnow aggregates Stoke Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STOK to receive live email and push alerts on every new disclosure.